Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML

Leukemia. 2012 Oct;26(10):2297-9. doi: 10.1038/leu.2012.152. Epub 2012 Jun 5.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimetabolites, Antineoplastic / therapeutic use*
  • Azacitidine / therapeutic use*
  • Biomarkers
  • CpG Islands
  • DNA Methylation
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Myelodysplastic Syndromes / drug therapy*
  • Neoplasms, Second Primary / drug therapy*
  • Promoter Regions, Genetic
  • Proportional Hazards Models
  • Risk
  • fas Receptor / analysis
  • fas Receptor / genetics*

Substances

  • Antimetabolites, Antineoplastic
  • Biomarkers
  • fas Receptor
  • Azacitidine